Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05038488 · ClinicalTrials.gov registry record · Phase 2
Phase 2a MIB-626 vs. Placebo COVID-19
A Phase 2 study, sponsored by Metro International Biotech.
- Completed
- Registry status
- Phase 2
- Development phase
- 42
- Enrollment target
NCT05038488: Completed Phase 2 study, sponsored by Metro International Biotech.
NCT05038488 is a Phase 2 study that has completed, run by Metro International Biotech. The registered enrollment target is 42 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (68% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05038488, a Phase 2 study, has completed, sponsored by Metro International Biotech.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 42 participants
- Enrollment target
Study Summary
The proposed phase 2a trial will determine whether MIB-626 treatment in adults with COVID-19 infection and stage 1 acute kidney injury is more efficacious than placebo in preventing worsening of kidney function, as assessed by longitudinal changes in serum creatinine concentration, and in attenuating the inflammatory response to the infection.
Primary Outcome
Change from baseline in serum cystatin C levels
Interventions
- DRUG Placebo
- DRUG MIB-626
- OTHER Home Treatment
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2021-10-26 |
| Est. Completion | 2023-08-17 |
| Phase | Phase 2 |
What the finished NCT05038488 record still lists
NCT05038488 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 42 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (68% lower).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT05038488 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05038488 about?
NCT05038488 is a clinical study titled "Phase 2a MIB-626 vs. Placebo COVID-19". The proposed phase 2a trial will determine whether MIB-626 treatment in adults with COVID-19 infection and stage 1 acute kidney injury is more efficacious than placebo in preventing worsening of kidney function, as assessed by longitudinal changes in serum creatinine concentration, and in attenuatin...
What is the current status of trial NCT05038488?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 42 participants. The study started on 2021-10-26. Estimated completion is 2023-08-17.
What interventions are being tested in trial NCT05038488?
The interventions under investigation include: Placebo (DRUG), MIB-626 (DRUG), Home Treatment (OTHER).
Who is sponsoring clinical trial NCT05038488?
This trial is sponsored by Metro International Biotech, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05038488's enrollment target sits among peer trials
42 1339th of 2000 higher than 649 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02852213 · 42 participants · Phase 1
A Single-Stage, Adaptive, Open-label, Dose Escalation Safety and Efficacy Study of AADC Deficiency in Pediatric Patients
- NCT03136146 · 42 participants · Phase 2
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia
- NCT03178149 · 42 participants · Phase 1
A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration
- NCT03663530 · 42 participants · NA
Circadian Misalignment and Energy Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI